Top Markets
Coin of the day
Johnson & Johnson Johnson & Johnson

Johnson & Johnson

JNJ
Rangering i aksjer #18
Johnson & Johnson, together with its subsidiaries, researches and develops,... Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Aksjekurs
$240.45
Markedsverdi
$579.46B
Endring (1 dag)
0.51%
Endring (1 år)
46.88%
Land
US
Handel Johnson & Johnson (JNJ)

Kategori

P/E-forhold for Johnson & Johnson (JNJ)
P/E-forhold per March 2026 TTM: 21.88
Ifølge Johnson & Johnson sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 21.88. Ved slutten av 2024 hadde selskapet en P/E på 24.53.
P/E-forholdshistorikk for Johnson & Johnson fra 2000 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
2026 (TTM) 21.88 16.71%
2025 18.75 -23.56%
2024 24.53 117.16%
2023 11.30 -47.70%
2022 21.60 -22.85%
2021 28.00 10.67%
2019 25.30 12.64%
2018 22.46 -92.21%
2017 288.31 1,504.75%
2016 17.97 0.04%
2014 17.96 -4.59%
2013 18.82 4.89%
2012 17.95 39.12%
2011 12.90 -11.36%
2010 14.55 15.26%
2008 12.63 -30.55%
2007 18.18 3.55%
2006 17.56 -23.07%
2005 22.82 7.99%
2003 21.14 -13.54%
2002 24.45 -22.65%
2001 31.60 -0.45%
2000 31.75 0.00%
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
42.86 95.87%
US
92.55 322.93%
US
20.85 -4.72%
CH
28.47 30.08%
GB
15.77 -27.93%
US
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.